Veterinary researcher collaborates on aerosol-based treatment for lung cancer

Veterinary researcher collaborates on aerosol-based treatment for lung cancer

Lung cancer patients may one day be able to breathe a sigh of relief because of a new potential treatment for the disease. Kansas State University’s Masaaki Tamura is collaborating on a National Institutes of Health-funded research project for a therapeutic compound that would be administered directly to the lungs in aerosol form. “The standard treatments for lung cancer include chemotherapy, radiation and surgery,” said Tamura, who is an associate professor of anatomy and physiology in the College of Veterinary. Read More

Indian chemical industry to grow significantly by 2020

Presently, the Indian chemical industry is showing tremendous resilience in adverse global conditions. The exports are set to witness growth in value and volume terms as compared to last year. These were some of the key points of discussion at the Chemexcil export awards function, held in Mumbai, India on 24 March. The Indian chemical industry is expected to reach $226 billion by 2020, from $147 billion in 2015, said Nirmala Sitharaman, minister for commerce and industry, who was also the chief guest at the Chemexcil. Read More

Wacker expands ketene production in Burghausen, Germany

MUNICH/ BURGHAUSEN, GERMANY: Wacker Biosolutions, the life sciences and biotechnology division of Wacker Group, is expanding its integrated ketene production at its Burghausen site, Germany. The company is building a further reactor for the manufacture of isopropenyl acetate (IPA) with an annual capacity of 2,500 metric tonnes. IPA is an important starting material for acetylacetone (AcAc), which is used in numerous applications, ranging from life sciences products through to construction and automotive applications. Read More

Merck sells biosimilars business to Fresenius

DARMSTADT, GERMANY: Merck said that it has sold its biosimilars business to Fresenius Kabi AG, a pharmaceutical company in Germany and a wholly owned subsidiary of the Fresenius SE & Co KGaA healthcare group. The decision to divest biosimilars is aligned with Merck’s strategy for its healthcare business sector to focus on its pipeline of innovative medicines. According to the terms agreed to the transaction, Merck will receive an upfront payment of €170 million, milestone payments of up to €500 million. Read More